Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 and Pembrolizumab in Advanced Non-Small Cell Lung Cancer
NCT05570825Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Apr 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SX-682 in non-small cell lung cancer (NSCLC), sponsored by University of Washington. Started Apr 2023; status: recruiting.
02
Drugs
SX-682
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05570825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570825.